Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29045309 | 1.00 | CTSK (0.41) | CTSKCTSSL3MBTL1ATMMAPT | |
| SCHEMBL1573827 | 0.88 | CTSS (0.42) | CTSKCTSSL3MBTL1MAPTALDH1A1 | |
| SCHEMBL1952090 | 0.88 | CTSS (0.42) | CTSKCTSSL3MBTL1MAPTALDH1A1 | |
| SCHEMBL469053 | 0.88 | CTSS (0.42) | CTSKCTSSL3MBTL1MAPTALDH1A1 | |
| SCHEMBL9420598 | 0.84 | RIPK1 (0.46) | CTSKCTSSL3MBTL1ATMMAPT | |
| Hydrochloric Acid SCHEMBL28325626 | 0.83 | ALDH1A1 (0.47) | ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL30541300 | 0.79 | PTGS2 (0.42) | CTSKCTSSMAPT | |
| SCHEMBL8704232 | 0.79 | CTSS (0.39) | CTSKCTSSL3MBTL1ATMMAPT | |
| SCHEMBL28368840 | 0.79 | PTGS2 (0.42) | CTSKCTSSMAPT | |
| SCHEMBL27636809 | 0.79 | CTSS (0.39) | CTSKCTSSL3MBTL1ATMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2024-11-07 | — | — | US | disclosed |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-01-09 | — | — | US | disclosed |
| CN-116547287-A | Inhibitors of APOL1 and methods of use thereof | 弗特克斯药品有限公司 | 2023-08-04 | — | — | CN | disclosed |
| EP-4204423-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
| WO-2022047031-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | CTSK 575/4885CTSS 632/4885L3MBTL1 2086/4885 |
| US-12421249-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | CTSK 575/4885CTSS 632/4885L3MBTL1 2086/4885 |
| US-20240368180-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | CTSK 575/4885CTSS 632/4885L3MBTL1 2086/4885 |
| US-11866446-B2 | Inhibitors of APOL1 and methods of using same | APOL1, PNLIP, APOB | CTSK 575/4885CTSS 632/4885L3MBTL1 2086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.